Literature DB >> 21558405

BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer.

Sheetal Bhan1, Sandeep S Negi, Chunbo Shao, Chad A Glazer, Alice Chuang, Daria A Gaykalova, Wenyue Sun, David Sidransky, Patrick K Ha, Joseph A Califano.   

Abstract

PURPOSE: Aim of this study was to determine whether BORIS (Brother of the Regulator of Imprinted Sites) is a regulator of MAGEA2, MAGEA3, and MAGEA4 genes in lung cancer. EXPERIMENTAL
DESIGN: Changes in expression of MAGEA genes upon BORIS induction/knockdown were studied. Recruitment of BORIS and changes in histone modifications at their promoters upon BORIS induction were analyzed. Luciferase assays were used to study their activation by BORIS. Changes in methylation at these promoters upon BORIS induction were evaluated.
RESULTS: Alteration of BORIS expression by induction/knockdown directly correlated with expression of MAGEA genes. BORIS was enriched at their promoters in H1299 cells, which show high expression of these cancer testis antigens (CTA), compared with normal human bronchial epithelial (NHBE) cells which show low expression of the target CTAs. BORIS induction in A549 cells resulted in increased amounts of BORIS and activating histone modifications at their promoters along with a corresponding increase in their expression. Similarly, BORIS binding at these promoters in H1299 correlates with enrichment of activating modifications, whereas absence of BORIS binding in NHBE is associated with enrichment of repressive marks. BORIS induction of MAGEA3 was associated with promoter demethylation, but no methylation changes were noted with activation of MAGEA2 and MAGEA4.
CONCLUSIONS: These data suggest that BORIS positively regulates these CTAs by binding and inducing a shift to a more open chromatin conformation with promoter demethylation for MAGEA3 or independent of promoter demethylation in case of MAGEA2 and MAGEA4 and may be a key effector involved in their derepression in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558405      PMCID: PMC3172963          DOI: 10.1158/1078-0432.CCR-11-0653

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

Review 1.  Functional consequences of histone modifications.

Authors:  Masayoshi Iizuka; M Mitchell Smith
Journal:  Curr Opin Genet Dev       Date:  2003-04       Impact factor: 5.578

Review 2.  Cancer-testis antigens: potential targets for cancer immunotherapy.

Authors:  Soudeh Ghafouri-Fard; Mohammad-Hossein Modarressi
Journal:  Arch Iran Med       Date:  2009-07       Impact factor: 1.354

3.  Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene BORIS.

Authors:  Teruhiko Suzuki; Natsuki Kosaka-Suzuki; Svetlana Pack; Dong-Mi Shin; Jeongheon Yoon; Ziedulla Abdullaev; Elena Pugacheva; Herbert C Morse; Dmitri Loukinov; Victor Lobanenkov
Journal:  Mol Cell Biol       Date:  2010-03-15       Impact factor: 4.272

4.  Expression of cancer/testis (CT) antigens in lung cancer.

Authors:  Kouhei Tajima; Yuichi Obata; Hiromi Tamaki; Masahiro Yoshida; Yao-Tseng Chen; Matthew J Scanlan; Lloyd J Old; Hiroyuki Kuwano; Takashi Takahashi; Toshitada Takahashi; Tetsuya Mitsudomi
Journal:  Lung Cancer       Date:  2003-10       Impact factor: 5.705

5.  An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes.

Authors:  G N Filippova; S Fagerlie; E M Klenova; C Myers; Y Dehner; G Goodwin; P E Neiman; S J Collins; V V Lobanenkov
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

6.  Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.

Authors:  Chad A Glazer; Ian M Smith; Michael F Ochs; Shahnaz Begum; William Westra; Steven S Chang; Wenyue Sun; Sheetal Bhan; Zubair Khan; Steven Ahrendt; Joseph A Califano
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

Review 7.  Cancer/testis (CT) antigens: potential targets for immunotherapy.

Authors:  Otavia L Caballero; Yao-Tseng Chen
Journal:  Cancer Sci       Date:  2009-08-01       Impact factor: 6.716

Review 8.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.

Authors:  Matthew J Scanlan; Ali O Gure; Achim A Jungbluth; Lloyd J Old; Yao-Tseng Chen
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

9.  Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.

Authors:  J Weber; M Salgaller; D Samid; B Johnson; M Herlyn; N Lassam; J Treisman; S A Rosenberg
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

10.  TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization.

Authors:  Wenyue Sun; Yan Liu; Chad A Glazer; Chunbo Shao; Sheetal Bhan; Semra Demokan; Ming Zhao; Michelle A Rudek; Patrick K Ha; Joseph A Califano
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

View more
  22 in total

1.  Investigation of fusion gene expression in HCT116 cells.

Authors:  Yanmei Zhang; Juan Ren; Mengdie Fang; Xiaoju Wang
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

2.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.

Authors:  Sanne Marlijn Janssen; Roy Moscona; Mounib Elchebly; Andreas Ioannis Papadakis; Margaret Redpath; Hangjun Wang; Eitan Rubin; Léon Cornelis van Kempen; Alan Spatz
Journal:  Cell Death Discov       Date:  2020-01-02

3.  Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma.

Authors:  Liang Han; Bin Jiang; Hao Wu; Shu Zhang; Xueguan Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  Intronic promoter drives the BORIS-regulated expression of FerT in colon carcinoma cells.

Authors:  Adar Makovski; Etai Yaffe; Sally Shpungin; Uri Nir
Journal:  J Biol Chem       Date:  2012-01-05       Impact factor: 5.157

5.  Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma.

Authors:  A Curioni-Fontecedro; R Pitocco; N L Schoenewolf; D Holzmann; D Soldini; R Dummer; S Calvieri; H Moch; D Mihic-Probst; A Fitsche
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

6.  Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.

Authors:  Leonardo Mirandola; Jose A Figueroa; Tam T Phan; Fabio Grizzi; Minji Kim; Rakhshanda Layeequr Rahman; Marjorie R Jenkins; Everardo Cobos; Cynthia Jumper; Raed Alalawi; Maurizio Chiriva-Internati
Journal:  Oncotarget       Date:  2015-02-20

7.  Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.

Authors:  Heidi Schwarzenbach; Corinna Eichelser; Bettina Steinbach; Josefine Tadewaldt; Klaus Pantel; Victor Lobanenkov; Dmitri Loukinov
Journal:  BMC Cancer       Date:  2014-11-03       Impact factor: 4.430

8.  Dose-dependent activation of putative oncogene SBSN by BORIS.

Authors:  Daria Gaykalova; Rajita Vatapalli; Chad A Glazer; Sheetal Bhan; Chunbo Shao; David Sidransky; Patrick K Ha; Joseph A Califano
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

Review 9.  The significance of epigenetic alterations in lung carcinogenesis.

Authors:  Ewa Brzeziańska; Agata Dutkowska; Adam Antczak
Journal:  Mol Biol Rep       Date:  2012-10-20       Impact factor: 2.316

10.  Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer.

Authors:  Hae Young Lee; Jong In Kim; Sung Ho Cho; Taek Yong Ko; Hyun Su Kim; Sung Dal Park; Sung Rae Cho; Hee Kyung Chang; Guk Jin Hwang; Sang Bong Jung
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.